HIV and Antiretroviral Therapy: Lipid Abnormalities and Associated Cardiovascular Risk in HIV-Infected Patients
- 1 September 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 49 (Supplement), S79-S85
- https://doi.org/10.1097/qai.0b013e318186519c
Abstract
It has been demonstrated that patients on highly active antiretroviral therapy are at increased risk for developing metabolic abnormalities that include elevated levels of serum triglycerides and low-density lipoprotein cholesterol and reduced levels of high-density lipoprotein cholesterol. This dyslipidemia is similar to that seen in the metabolic syndrome, raising the concern that highly active antiretroviral therapy also potentially increases the risk for cardiovascular complications. This paper reviews the contribution of both HIV infection and the different components of highly active antiretroviral therapy to dyslipidemia and the role of these abnormalities toward increasing the risk of cardiovascular disease in HIV-infected patients; therapeutic strategies to manage these risks are also considered.Keywords
This publication has 23 references indexed in Scilit:
- Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)Atherosclerosis, 2007
- Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (AI424-097) 48-Week ResultsClinical Infectious Diseases, 2007
- Class of Antiretroviral Drugs and the Risk of Myocardial InfarctionThe New England Journal of Medicine, 2007
- The use of the Framingham equation to predict myocardial infarctions in HIV‐infected patients: comparison with observed events in the D:A:D StudyHIV Medicine, 2006
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Combination Antiretroviral Therapy and the Risk of Myocardial InfarctionThe New England Journal of Medicine, 2003
- Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected menAIDS, 2003
- Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus InfectionThe New England Journal of Medicine, 2003
- Cardiovascular and Cerebrovascular Events in Patients Treated for Human Immunodeficiency Virus InfectionThe New England Journal of Medicine, 2003
- Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complexThe Lancet, 1992